Alimentiv and Satisfai Health have expanded their partnership to expedite the development of new imaging technologies for gastrointestinal (GI) disease challenges.
Satisfai Health offers artificial intelligence (AI)-based medical solutions for GI diseases. On the other hand, Alimentiv is a GI contract research organisation (CRO) specialising in IBD medical imaging.
Certai software of Satisfai Health is an assistive scoring tool for ulcerative colitis (UC).
Under the partnership, clinical trial sponsors will have access to enhanced analysis of endoscopic videos through Certai.
Satisfai Health chairman and founder Michael Byrne said: “Certai offers precise disease activity assessment (from frame to segment to video) for clinical trials.
“By improving trial quality and efficiency, Certai provides the most comprehensive solution for advancing IBD research.”
Certai’s AI was developed using a diverse, anonymised global dataset of IBD colonoscopy videos.
It was trained and validated with data labelling and clinical oversight from international IBD experts and Alimentiv central readers.
The tool is accessible through Alimentiv’s Notō platform, a custom software solution. Notō supports image review and centralised scoring for multiple modalities: endoscopy, histopathology, magnetic resonance enterography (MRI/MRE), and intestinal ultrasound (IUS).
Alimentiv CEO Pierre Gaudreault said: “AI-powered standardisation of disease scoring provides unprecedented insights, transforming data analysis and ultimately leading to better treatment outcomes for patients in clinical trials.
“As the leader in the field, Alimentiv will continue to lead this space and invest in innovative imaging solutions to provide more accurate analyses, highly competitive trial costs, and support sponsors with faster timelines.”
Alimentiv provides clinical, medical imaging, and precision medicine services. The company partners with pharmaceutical and biotechnology firms to advance new therapies and accelerate their time to market.
Satisfai Health offers real-time analysis of medical imagery, providing clinicians with decision-support intelligence.
In January this year, the company secured Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its Veritai tool. The software aids in the detection, delineation, and characterisation of neoplastic (cancerous) Barrett’s Esophagus (BE).
Recently, Alimentiv, Satisfai Health, and Virgo Surgical Video Solutions partnered to advance clinical trials for inflammatory bowel disease (IBD) and related GI conditions.
